WSPH Task Force Recommendations

WSPH Task Force Recommendations

For adult patients with PAH,

World Symposium on Pulmonary Hypertension (WSPH) recommends placement of activin signaling inhibitor (ASI) WINREVAIR (sotatercept) in PAH treatment algorithm

In the 7th WSPH task force report Treatment Algorithm for Pulmonary Hypertension, the WSPH task force provides a recommended update to the treatment algorithm for PAH, which now includes the use of an ASI—the first treatment option to act on a completely novel pathway.¹

The WSPH recommends the consideration of WINREVAIR, the first and only ASI, 3 to 4 months after initiation of upfront therapy for patients who have not achieved low risk status^1-12

Therapy for group 1 PAH, including iPAH, including iPAH, hPAH, DT-PAH, and CTD-PAH¹

Adapted from Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J.
Published online August 29, 2024. doi:10.1183/13993003.01325-2024

The WSPH task force provides recommendations to optimize patient care:

WSPH Recommendation

Consider adding WINREVAIR, the first and only ASI, as soon as 3 months after PAH diagnosis for patients who have not achieved low risk status^1-12

CTD-PAH = connective tissue disease pulmonary arterial hypertension; DT-PAH = drug and toxin pulmonary arterial hypertension; ERA = endothelin receptor antagonist; hPAH = hereditary pulmonary arterial hypertension; iPAH = idiopathic pulmonary arterial hypertension; IV = intravenous; PAH = pulmonary arterial hypertension; PDE5i = phosphodiesterase 5 inhibitor; PPA = prostacyclin pathway agent; Rx = prescription; SC = subcutaneous; sGCS = soluble guanylate cyclase stimulator.

[SSI PLACEHOLDER]

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum in nu Ila odio. Donec vitae libero hendrerit, tincidunt erat a, aliquam arcu. Proin vel dictum risus. Nunc aliquam pellentesque magna, ut dignissim mi viverra sed. Nunc eget dolor quis erat rhoncus varius ut vel urna. Etiam commodo odio felis, nee mattis ex lobortis quis. Nulla eleifend eleifendjusto. Phasellus varius tempor lacinia. Suspendisse lacus ante, consequat nee orci et, congue dictum lectus. Phasellus lectus nisi, maximus ac sem ut, varius blandit sapien. Nam efficitur sapien sed dui mattis, nee varius elit egestas. Mauris commodo nee neque sit amet sodales.

Ut congue imperdiet diam, non faucibus sapien finibus non. Maecenas lacus mi, sodales non convallis non, malesuada at mi. Maecenas risus eras, luctus eget dapibus quis, semper vel massa. Phasellus euismod tortor id tortor interdum maxim us. Etiam sodales erat sit amet quam sollicitudin hendrerit. Sed sollicitudin lectus ut mi lobortis, vel efficitur arcu ullamcorper. Nam aliquam eget ligula sit amet feugiat. Sed vulputate, arcu et cursus ultrices, velit nisl feugiat mauris, ut eleifend ante dolor vitae massa. Praesent lacinia purus leo, quis porta ipsum commodo in. Donec pretium leo ante, id faucibus purus bibendum id. Donec iaculis augue augue, aliquet pulvinar mi vehicula in. Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas. Phasellus enim massa, tempor non elit congue, rutrum rhoncus nulla. Donec finibus eu ipsum vitae porttitor. Vestibulum tincidunt tincidunt quam, id lobortis eras luctus ac. Pellentesque faucibus lacus vel elit viverra fringilla.

References:
1. Chin KM, Gaine SP, Gerges C, et al. Treatment algorithm for pulmonary arterial hypertension. Eur Respir J. Published online August 29, 2024. doi:10.1183/13993003.01325-2024 2. Hoeper MM, Badesch DB, Ghofrani HA, et al; STELLAR Trial Investigators. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388(16):1478-1490. 3. Treposuvi. Summary of Product Characteristics. AOP Orphan Ltd; 2024. 4. Adempas. Summary of Product Characteristics. Bayer AG; 2023. 5. Ventavis. Summary of Product Characteristics. Bayer AG; 2023. 6. Adcirca. Summary of Product Characteristics. Eli Lilly Nederland BV; 2024. 7. Volibris. Summary of Product Characteristics. GlaxoSmithKline (Ireland) Limited; 2024. 8. Opsumit. Summary of Product Characteristics. Janssen-Cilag International NV; 2023. 9. Tracleer. Summary of Product Characteristics. Janssen-Cilag International NV; 2024. 10. Uptravi. Summary of Product Characteristics. Janssen-Cilag International NV; 2024. 11. Flolan. Summary of product characteristics, labelling and package leaflet. EMA; 2012. 12. Revatio. Summary of Product Characteristics. Upjohn EESV; 2024. 13. Hemnes AR, Celermajer DS, D’Alto M, et al. Pathophysiology of the right ventricle and its pulmonary vascular interaction. Eur Respir J. Published online August 29, 2024. doi:10.1183/13993003.01321-2024 14. Dardi F, Boucly A, Benza R, et al. Risk stratification and treatment goals in pulmonary arterial hypertension. Eur Respir J. Published online August 29, 2024. doi:10.1183/13993003.01323-2024